NICE
@NICEComms
Followers
241K
Following
3K
Media
9K
Statuses
17K
Official feed of NICE - National Institute for Health and Care Excellence. We produce evidence-based health and social care guidance. Tweets by the comms team.
London and Manchester, UK
Joined October 2009
NICE CEO, Dr Sam Roberts shares how the government’s 10 Year Plan empowers NICE with 3 game-changing priorities to drive smarter spending, make parallel decisions and rollout faster and fairer access to healthtech. 🔗 https://t.co/8LPmO6ZPuJ
0
0
1
We're consulting on a disease-specific reference case extension for obesity treatments in adults. This will set standards for economic modelling of medicines, digital tech and surgical interventions. Respond by 3 December: https://t.co/4VMBAVj2tV
0
0
1
$ASTS is a smart and ambitious company that seeks to build a space-based network provider for existing Mobile Network Operators (MNOs) like AT&T, Verizon, and Vodafone. Consensus expectations are for hyper growth, but the business of launching satellites is long, complicated and
4
7
23
Just over 62,000 people with moderate to severe chronic hand eczema could benefit from a new cream treatment. We've published final guidance today recommending use of delgocitinib. Find out more: https://t.co/nExNbrbdyu
0
0
4
We’ve highlighted the priority health areas where we'll make the greatest impact on patient care and NHS resources this year. From biosimilar medicines to mental health, obesity to sepsis – discover why each area matters⬇️ https://t.co/qdK0sHNTbF
0
1
1
How does NICE ensure the NHS gets guidance on what matters most? Each year we publish our forward view, giving a clear line of sight on guidance that may affect service planning and commissioning decisions. Learn more⬇️ https://t.co/mtAFUyxeJe
2
1
3
Our antenatal care resources help commissioners and providers achieve the best outcomes best outcomes for patients during pregnancy. Includes the latest data, case studies and @NHS_RHO and @NHSEngland resources: https://t.co/EyQcaSyepR
0
0
4
Our reaction to the news that @NICEComms has recommended generic abiraterone for prostate cancer which will benefit thousands of patients by increasing access and saving the NHS millions of pounds. This reverses NICE's 2021 guidance when the treatment didn't represent value for
0
1
2
Mark Samuels, chief executive of @Medicines_UK has welcomed our recommendation of generic abiraterone and the innovative approach taken to this evaluation⤵️
0
1
1
The review is part of NICE's new Whole Lifecycle Approach – making recommendations more responsive to changes in evidence, pricing and clinical practice.
1
0
0
We’ve published final draft guidance recommending abiraterone and its generic variants for treating newly diagnosed high-risk hormone‑sensitive metastatic prostate cancer. Full story here⤵️ https://t.co/NGaKjHFueF
1
1
4
NICE is part of a new international collaboration examining how we evaluate treatments worldwide. The Health Economics Methods Advisory (HEMA) - working with @icer_review and @CDA_CMC - has just published its first draft report. Learn more in our blog: https://t.co/mXPrA6cCWH
0
0
4
From bedside to boardroom: an Executive MSc journey Dr Savvas Vlachos, alum of the Exec MSc in Healthcare Decision-Making, has been featured by @NICEComms for his inspiring career journey. Read his story here: https://t.co/Thl2Rfr4mz 2025 Scholarships: https://t.co/WAtJNKU9BA
0
2
0
3 million people in the UK live with MASH—a serious liver condition with no licensed treatments. As new medicines are developed, we're working with patients, clinicians and industry on a common framework to help people access them quickly. 🔗 https://t.co/BIPvz73Qnz
0
0
2
Using NICE’s simplified, cost comparison approach to this technology appraisal the final draft guidance for darolutamide was published faster.
0
0
0
Peter Johnson, national clinical director for cancer @NHSEngland, says the treatment being approved is good news for patients.
1
0
0
The new treatment combination has been welcomed by Helen Knight, our director of Medicines Evaluation, as another vital option for people with advanced #prostatecancer
1
0
0
Thousands of people with advanced prostate cancer set to benefit after we recommended a new treatment combination today. Find out more about darolutamide: https://t.co/eONqHtiB0c
1
4
5
Our menopause guideline helps healthcare professionals discuss treatment options for symptoms. Find evidence-based recommendations to support conversations with patients⬇️ https://t.co/MzmzHJADs7
👩 Menopause will be included in NHS health checks for the first time to help millions of women get the support they need. GP @Dr_Ellie explains why this is important ⬇️ We're overhauling women's healthcare as we build an NHS fit for the future. More: https://t.co/qBatVSf22q
0
2
2
🗺��Discover how we’re working with international partners to research the most pressing topics in global health decision making and the role the new Health Economics Methods Advisory group will play, at #NICEConf26. 🎟️Book now to find out more on 17 March: https://t.co/imauVxBGpj
0
0
2
We're seeking professional experts in technologies that support self-monitoring of vision change for people with macular disease, as well as patient experts with lived experience. Help us develop guidance by applying via our questionnaires: https://t.co/eQKNcWzoWA
0
0
2